Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima–media thickness and endothelium-dependent vasodilation
Abstract It has been suggested that there is an ongoing subclinical inflammation in familial Mediterranean fever (FMF) patients also in attack-free periods as well. Due to this ongoing inflammation, endothelial dysfunction (ED) may develop. Previously, ED has been suggested to increase the risk of the atherosclerosis and cardiovascular disease (CVD). Endocan is recognized as a specific molecule of the endothelium and has been shown to increase in some cases associated with inflammation. However, there is not sufficient data whether those with FMF could develop ED in the early period of life. In this study, we aimed to investigate ED and its relation with endocan in young FMF patients. A total of 57 male patients diagnosed with FMF according to the Tel Hashomer criteria and a total of 33 healthy males with similar characteristics to the patient group were included in this research. Complete blood count, erythrocyte sedimentation rate (ESR), fibrinogen, serum glucose, serum LDL cholesterol (LDL-C) and triglyceride (TG), asymmetric dimethylarginine (ADMA), and endocan levels were tested from fasting blood samples. Moreover, carotid intima–media thickness (CIMT) and flow-mediated dilatation (FMD) were measured. The endocan levels of the FMF patients during an attack-free period were significantly higher than those of the control group (p < 0.001). On the other hand, FMD measurements were significantly lower among FMF patients (p < 0.001). ADMA levels were higher in the patient group; however, this difference was similar (p > 0.05). CIMT values were similar among FMF patients and healthy controls (p > 0.05). These results have suggested that ED may develop in the patients with FMF who have no additional CVD risk, even during young adulthood, and endocan may be a favorable biomarker at demonstration of ED than ADMA among FMF patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 36(2017), 9 vom: 10. Jan., Seite 2071-2077 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ozalper, Veysel [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Carotid intima–media thickness |
| doi: |
10.1007/s10067-016-3532-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR008527008 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR008527008 | ||
| 003 | DE-627 | ||
| 005 | 20230519124738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-016-3532-2 |2 doi | |
| 035 | |a (DE-627)SPR008527008 | ||
| 035 | |a (SPR)s10067-016-3532-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Ozalper, Veysel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima–media thickness and endothelium-dependent vasodilation |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract It has been suggested that there is an ongoing subclinical inflammation in familial Mediterranean fever (FMF) patients also in attack-free periods as well. Due to this ongoing inflammation, endothelial dysfunction (ED) may develop. Previously, ED has been suggested to increase the risk of the atherosclerosis and cardiovascular disease (CVD). Endocan is recognized as a specific molecule of the endothelium and has been shown to increase in some cases associated with inflammation. However, there is not sufficient data whether those with FMF could develop ED in the early period of life. In this study, we aimed to investigate ED and its relation with endocan in young FMF patients. A total of 57 male patients diagnosed with FMF according to the Tel Hashomer criteria and a total of 33 healthy males with similar characteristics to the patient group were included in this research. Complete blood count, erythrocyte sedimentation rate (ESR), fibrinogen, serum glucose, serum LDL cholesterol (LDL-C) and triglyceride (TG), asymmetric dimethylarginine (ADMA), and endocan levels were tested from fasting blood samples. Moreover, carotid intima–media thickness (CIMT) and flow-mediated dilatation (FMD) were measured. The endocan levels of the FMF patients during an attack-free period were significantly higher than those of the control group (p < 0.001). On the other hand, FMD measurements were significantly lower among FMF patients (p < 0.001). ADMA levels were higher in the patient group; however, this difference was similar (p > 0.05). CIMT values were similar among FMF patients and healthy controls (p > 0.05). These results have suggested that ED may develop in the patients with FMF who have no additional CVD risk, even during young adulthood, and endocan may be a favorable biomarker at demonstration of ED than ADMA among FMF patients. | ||
| 650 | 4 | |a Carotid intima–media thickness |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Endocan |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Endothelial dysfunction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Familial Mediterranean fever |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Flow-mediated dilatation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kara, Muammer |e verfasserin |4 aut | |
| 700 | 1 | |a Tanoglu, Alpaslan |e verfasserin |4 aut | |
| 700 | 1 | |a Cetındaglı, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturker, Coskun |e verfasserin |4 aut | |
| 700 | 1 | |a Hancerlı, Yusuf |e verfasserin |4 aut | |
| 700 | 1 | |a Hıra, Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Kara, Kemal |e verfasserin |4 aut | |
| 700 | 1 | |a Beyazıt, Yavuz |e verfasserin |4 aut | |
| 700 | 1 | |a Yazgan, Yusuf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d London : Springer, 1982 |g 36(2017), 9 vom: 10. Jan., Seite 2071-2077 |w (DE-627)SPR008480389 |w (DE-600)1480901-1 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2017 |g number:9 |g day:10 |g month:01 |g pages:2071-2077 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10067-016-3532-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.83 |q ASE |
| 951 | |a AR | ||
| 952 | |d 36 |j 2017 |e 9 |b 10 |c 01 |h 2071-2077 | ||